ACADIA Pharmaceuticals Inc. (ACAD) is a pharmaceutical company developing drugs for patients with central nervous system disorders.The company’s lead product is Nuplazid (pimavanserin), which received FDA approval as recently as April of this year to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.A phase II study exploring the utility of Nuplazid for the treatment of Alzheimer’s disease psychosis is underway, among other indications. The top line results from the Alzheimer’s disease psychosis study are expected this month.Given the fact that Nuplazid, which carries a price tag of $13,500 per patient for a year, is being tested for a couple of other indications too, some analysts believe that it could become a blockbuster. ACAD has lost over 20% of its value so far this year, and trades around $28.